In COVID-19 clinical update #91, Dr. Griffin discusses final results of molnupiravir trial, Omicron variant of concern, outcomes in B-cell depleted patients, recovery in T-cell depleted macaques, peptide for induction of T cell immunity, high respiratory viral RNA loads in infants, IgA and T cells transferred to breast milk after vaccination, sensitivity and specificity of ID NOW, post-acute sequelae at 12 months, disease in low and middle income countries. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Update on Molnupiravir results (Merck) Omicron (Wikipedia) P681H and IFN resistance (bioRxiv) Synthetic DMARDS and disease severity (Ann Rheum Dis) Recovery in T cell depleted macaques (mBio) T-cell inducing peptide (Nature) Respiratory viral RNA load in infants (J Inf Dis) IgA and T cells in breast milk (Cell Rep) ID NOW specificity and sensitivity (J Clinical Viral) Risk prediction algorithm (Thorax) PASC in adults at 12 months (Front Med) Letters read on TWiV 837 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]